SI-BONE INC (SIBN)

US8257041090 - Common Stock

13.25  +0.2 (+1.53%)

After market: 13.25 0 (0%)

Fundamental Rating

3

SIBN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of SIBN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SIBN is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SIBN has reported negative net income.
SIBN had a negative operating cash flow in the past year.
In the past 5 years SIBN always reported negative net income.
In the past 5 years SIBN always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of SIBN (-16.48%) is comparable to the rest of the industry.
The Return On Equity of SIBN (-22.67%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -16.48%
ROE -22.67%
ROIC N/A
ROA(3y)-29.14%
ROA(5y)-27.96%
ROE(3y)-43.35%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 77.70%, SIBN belongs to the top of the industry, outperforming 90.37% of the companies in the same industry.
In the last couple of years the Gross Margin of SIBN has declined.
SIBN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.57%
GM growth 5Y-2.87%

More info and screens

6

2. Health

2.1 Basic Checks

SIBN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SIBN has more shares outstanding
SIBN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SIBN has been reduced compared to a year ago.

2.2 Solvency

SIBN has an Altman-Z score of 3.77. This indicates that SIBN is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.77, SIBN is doing good in the industry, outperforming 71.12% of the companies in the same industry.
SIBN has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
SIBN has a Debt to Equity ratio of 0.22. This is comparable to the rest of the industry: SIBN outperforms 52.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 3.77
ROIC/WACCN/A
WACC9.18%

2.3 Liquidity

A Current Ratio of 8.25 indicates that SIBN has no problem at all paying its short term obligations.
The Current ratio of SIBN (8.25) is better than 90.37% of its industry peers.
SIBN has a Quick Ratio of 7.22. This indicates that SIBN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SIBN (7.22) is better than 89.84% of its industry peers.
Industry RankSector Rank
Current Ratio 8.25
Quick Ratio 7.22

More info and screens

6

3. Growth

3.1 Past

SIBN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.69%, which is quite impressive.
SIBN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.98%.
The Revenue has been growing by 20.18% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)22.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)18.98%
Revenue growth 3Y23.69%
Revenue growth 5Y20.18%
Sales Q2Q%18.6%

3.2 Future

Based on estimates for the next years, SIBN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.19% on average per year.
SIBN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.30% yearly.
EPS Next Y29.49%
EPS Next 2Y19.99%
EPS Next 3Y17.19%
EPS Next 5YN/A
Revenue Next Year20.42%
Revenue Next 2Y18.9%
Revenue Next 3Y18.3%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SIBN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SIBN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as SIBN's earnings are expected to grow with 17.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.99%
EPS Next 3Y17.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SIBN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SI-BONE INC

NASDAQ:SIBN (12/20/2024, 8:00:01 PM)

After market: 13.25 0 (0%)

13.25

+0.2 (+1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners92.29%
Inst Owner Change-1.51%
Ins Owners2.65%
Ins Owner Change2.14%
Market Cap555.71M
Analysts84
Price Target23.69 (78.79%)
Short Float %2.95%
Short Ratio3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.19%
Min EPS beat(2)22.01%
Max EPS beat(2)34.37%
EPS beat(4)4
Avg EPS beat(4)19.04%
Min EPS beat(4)5.34%
Max EPS beat(4)34.37%
EPS beat(8)8
Avg EPS beat(8)21.92%
EPS beat(12)9
Avg EPS beat(12)12.85%
EPS beat(16)11
Avg EPS beat(16)9.63%
Revenue beat(2)1
Avg Revenue beat(2)-0.04%
Min Revenue beat(2)-2.34%
Max Revenue beat(2)2.26%
Revenue beat(4)3
Avg Revenue beat(4)0.73%
Min Revenue beat(4)-2.34%
Max Revenue beat(4)2.26%
Revenue beat(8)7
Avg Revenue beat(8)2.58%
Revenue beat(12)9
Avg Revenue beat(12)1.59%
Revenue beat(16)10
Avg Revenue beat(16)1.22%
PT rev (1m)0%
PT rev (3m)-1.42%
EPS NQ rev (1m)8.91%
EPS NQ rev (3m)18.67%
EPS NY rev (1m)11.93%
EPS NY rev (3m)11.93%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)-1.42%
Revenue NY rev (1m)-0.51%
Revenue NY rev (3m)-0.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.54
P/FCF N/A
P/OCF N/A
P/B 3.37
P/tB 3.37
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS3.74
BVpS3.93
TBVpS3.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.48%
ROE -22.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.7%
FCFM N/A
ROA(3y)-29.14%
ROA(5y)-27.96%
ROE(3y)-43.35%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.57%
GM growth 5Y-2.87%
F-Score3
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 196.87%
Cap/Sales 5.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.25
Quick Ratio 7.22
Altman-Z 3.77
F-Score3
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)241.69%
Cap/Depr(5y)253.96%
Cap/Sales(3y)7.21%
Cap/Sales(5y)5.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y29.49%
EPS Next 2Y19.99%
EPS Next 3Y17.19%
EPS Next 5YN/A
Revenue 1Y (TTM)18.98%
Revenue growth 3Y23.69%
Revenue growth 5Y20.18%
Sales Q2Q%18.6%
Revenue Next Year20.42%
Revenue Next 2Y18.9%
Revenue Next 3Y18.3%
Revenue Next 5YN/A
EBIT growth 1Y7.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.07%
EBIT Next 3Y28.44%
EBIT Next 5YN/A
FCF growth 1Y55.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.6%
OCF growth 3YN/A
OCF growth 5YN/A